Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07357415 · ClinicalTrials.gov registry record · Phase 3
A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight
A Phase 3 study of Obesity and Overweight, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 600
- Enrollment target
- 20
- Study locations
NCT07357415: Recruiting Phase 3 study of Obesity and Overweight, sponsored by Eli Lilly and Company.
NCT07357415 is a Phase 3 study of Obesity and Overweight that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 600 participants, below the 818-participant average among 1,053 other Obesity trials with a reported enrollment target (27% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07357415, a Phase 3 study of Obesity and Overweight, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 600 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to investigate the efficacy and safety of different retatrutide dose escalation schemes in participants without type 2 diabetes who have obesity or overweight. Participation in the study will last about 113 weeks.
Conditions Studied
Interventions
- DRUG Retatrutide
Study Locations (20)
Texas
- Velocity Clinical Research, Dallas - Dallas
- Cedar Health Research - Texas Native Health - Dallas
- Cedar Health Research - Dallas
- Cedar Health Research - Fort Worth - Fort Worth
California
- Care Access - Huntington Beach - Huntington Beach
- Los Angeles Institute for Metabolic Research - Los Angeles
Florida
- New Horizon Research Center - Miami
- Encore Medical Research - Weston - Weston
New York
- NYC Research INC - Long Island City
- Weill Cornell Medical College - New York
Arizona
- Arizona Research Center - Phoenix
Hawaii
- Pacific Diabetes & Endocrine Center - Honolulu
Kentucky
- L-MARC Research Center - Louisville
Massachusetts
- Brigham and Women's Hospital Diabetes Program - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2026-01-24 |
| Est. Completion | 2028-11 |
| Phase | Phase 3 |
What NCT07357415 shows while recruiting
NCT07357415 is an interventional study that assigns participants to a tested intervention. The registered 600 participants enrollment target is mid-sized for trials with a published cap, below the 818-participant average among 1,053 other Obesity trials with a reported enrollment target (27% lower).
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 1 intervention - of which Retatrutide is the first listed.
NCT07357415 names 20 study sites across 14 states, led by Texas, California, Florida.
Frequently Asked Questions
What is clinical trial NCT07357415 about?
NCT07357415 is a clinical study titled "A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight". The purpose of this study is to investigate the efficacy and safety of different retatrutide dose escalation schemes in participants without type 2 diabetes who have obesity or overweight. Participation in the study will last about 113 weeks.
What is the current status of trial NCT07357415?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 600 participants. The study started on 2026-01-24. Estimated completion is 2028-11.
What conditions does trial NCT07357415 study?
This clinical trial studies the following conditions: Obesity, Overweight.
What interventions are being tested in trial NCT07357415?
The interventions under investigation include: Retatrutide (DRUG).
Who is sponsoring clinical trial NCT07357415?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07357415 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Hawaii, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07357415's enrollment target sits among peer trials
600 117th of 1053 higher than 934 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
RECRUITING · Phase 3
-
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
RECRUITING · Phase 3
-
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
RECRUITING · Phase 3
-
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004317 · 600 participants · Phase 4
Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
- NCT00209235 · 600 participants · NA
Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments
- NCT01473784 · 600 participants · NA
Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
- NCT01866371 · 600 participants
High Resolution Retinal Imaging
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI